glp 1 vs sglt2 cardioprotective effects Frontiers Criteria for recommendation of SGLT2

Injectable semaglutide, administered subcutaneously once weekly, has a half-life of approximately one week and reaches steady-state concentrations after 4-5 weeks of treatment

The results of both animal and cellular studies have demonstrated that in the context of hyperglycemia, the hearts capacity to utilize glucose is diminished, which in turn promotes oxidative stress and inflammation in myocardial cells

Non-invasive, non-disruptive

One potentially relevant observation is that GHK-Cu exposure may increase intracellular copper uptake, which may conceivably support enzymatic activity involved in collagen processing

Helman G, Caldovic L, Whitehead MT, Simons C, Brockmann K, et al